Barclays PLC Lucid Diagnostics Inc. Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Barclays PLC holds 120,002 shares of LUCD stock, worth $144,002. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120,002
Previous 120,002
-0.0%
Holding current value
$144,002
Previous $138,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding LUCD
# of Institutions
72Shares Held
15.4MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA4.13MShares$4.95 Million0.0% of portfolio
-
Masters Capital Management LLC Atlanta, GA2.73MShares$3.27 Million0.13% of portfolio
-
Geode Capital Management, LLC Boston, MA1.58MShares$1.89 Million0.0% of portfolio
-
Luminus Management LLC Houston, TX913KShares$1.1 Million0.86% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL738KShares$885,9320.0% of portfolio
About Lucid Diagnostics Inc.
- Ticker LUCD
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 38,568,500
- Market Cap $46.3M
- Description
- Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...